Bayer sees no reason to re-evaluate the legal risks from recently acquired Monsanto after the U.S. unit was ordered to pay damages in a lawsuit over alleged links between weed-killer glyphosate and cancer, Reuters reports, citing German daily Handelsblatt. “The safety assessment of glyphosate has not changed since the time of the acquisition. If that were to change and we were to find that something was missed during the due diligence we would act accordingly. But that is not the case,” CEO Werner Baumann said, adding the full extent of current glyphosate litigation was not foreseeable when Bayer assessed the value of the company.
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.